**Acknowledgements**

Special thanks to cardiac surgeons and anesthesiologists from the Emergency Institute for Cardiovascular Diseases "C.C.Iliescu", Bucharest, Romania

revascularization: the GUSTO IV-ACS randomised trial. Lancet. (2001). CrossRefMed‐

The Antiagregant Treatment After Coronary Artery Surgery Depending on Cost – Benefit Report

http://dx.doi.org/10.5772/54467

311

[10] Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study: Fragmin and Fast Revasculariza‐ tion During Instability in Coronary Artery Disease (FRISC II) InvestigatorsLancet.

[11] Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial: FRISC II Investigators: Fast Revascularisation During Instability in Coronary Artery DiseaseLancet. (2000).

[12] Cannon, C. P, Weintraub, W. S, Demopoulos, L. A, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. (2001). CrossRefMedline,

[13] Berkowitz, S. D, Granger, C. B, Pieper, K. S, et al. for the Global Utilization of Strepto‐ kinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) I Investigators. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation. (1997). Abstract/FREE Full Text, 95,

[14] Fox KAAPoole-Wilson PA, Henderson RA, et al, for the Randomized Intervention Trial of Unstable Angina (RITA) Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet. (2002). CrossRefMedline, 360,

[15] Fox, K. A. A, Mehta, S. R, Peters, R, Zhao, F, Lakkis, N, Gersh, B. J, & Yusuf, S. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome- The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial;

[16] The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of CardiologyEspert consensus document on the use of antiplatelet agents. Eur Heart J. (2004). PubMed], 25, 166-81.

[17] Guyatt, G, Schunëmann, H, Cook, D, et al. Grade of recommendation for antithrom‐

[18] Patrono, C, Coller, B, Fitzgerald, G. A, Hirsh, J, & Roth, G. Platelet active drugs: the relationships among dose, effectiveness and side effects. Chest. (2004). S-64S.[PubMed]

[19] Servin, F. Low-dose aspirin and clopidogrel: how to act in patients scheduled for day

surgery. Curr Opin Anaesthesiol. (2007). PubMed], 20, 531-4.

line, 357, 1915-1924.

(1999). CrossRefMedline, 354, 708-715.

CrossRefMedline, 356, 9-16.

Circulation. (2004). , 110, 1202-1208.

botic agents. Chest. (2001). S-7S.[PubMed]

344, 1879-1887.

2508-2516.

743-751.
